Intravenous thrombolysis for acute ischemic stroke in Asia

Expert Review of Neurotherapeutics

Volumn 12, Issue 2, 2012, Pages 209-217

  Sharma, Vijay K ^a   Ng, Kay W P ^a   Venketasubramanian, Narayanaswamy ^a   Teoh, Hock L ^a   Chan, Bernard P L ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

acute ischemic stroke; Asian; developing countries; thrombolysis; tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ASIA; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUCASIAN; DRUG EFFICACY; DRUG SAFETY; HUMAN; JAPANESE; LOW DRUG DOSE; OBSERVATIONAL STUDY; REVIEW;

ASIA; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84856622669     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.148     Document Type: Review

References (57)

1. World Health Organization. The World Health Report 2003: shaping the future. World Health Organization, Geneva, Switzerland (2003).
2. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol. 3(7), 391-393 (2004). (Pubitemid 38789131)
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 349(9067), 1269-1276 (1997). (Pubitemid 27192468)
4. Fagan S, Morgenstern L, Pettita A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 50(4), 883-890 (1998). (Pubitemid 28212810)
5. Chambers M, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 5(2), 85-97 (2002).
6. Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J. Clin. Epidemiol. 52(3), 259-271 (1999). (Pubitemid 29148438)
7. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 36(11), 2500-2503 (2005). (Pubitemid 41566988)
8. Rha JH, Saver JL. The impact of re-canalization on ischemic stroke outcome: a meta-analysis. Stroke 38(3), 967-973 (2007). (Pubitemid 46568460)
9. Thomassen L, Waje-Andreassen U, Naess H, Aarseth J, Russell D. Doppler ultrasound and clinical findings in patients with acute ischemic stroke treated with intravenous thrombolysis. Eur. J. Neurol. 12(6), 462-465 (2005). (Pubitemid 40768666)
10. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581-1587 (1995).
11. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 274(13), 1017-1025 (1995).
12. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352(9136), 1245-1251 (1998). (Pubitemid 28470336)
13. Clark WM, Albers GW, Madden KP, Hamilton S. The rt-PA (alteplase) 0-to 6-hour acute stroke trial, part A (A0267g): results of a double blind, placebo-controlled, multicenter study. Stroke 31(4), 811-816 (2000). (Pubitemid 30198420)
14. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study -a randomized controlled trial. JAMA 282(21), 2019-2026 (1999).
15. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 363(9411), 768-774 (2004).
16. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317-1329 (2008).
17. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST): an observational study. Lancet 369(9558), 275-282 (2007). (Pubitemid 46138121)
18. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375(9727), 1695-1703 (2010).
19. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23(5), 632-640 (1992).
20. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes. Stroke 23(5), 641-645 (1992).
21. Haley EC, Brott TG, Sheppard GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 24(7), 1000-1004 (1993). (Pubitemid 23201457)
22. Khatri P, Broderick JP, Pancioli AM. Risk of thrombolysis-associated intracerebral hemorrhage: the need to compare apples with apples. Stroke 36(6), 1109-1110 (2005). (Pubitemid 40798720)
23. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb. Haemost. 87(3), 544-546 (2002). (Pubitemid 34232504)
24. Iso H, Folson AR, Sato S, et al. Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler. Thromb. 13(6), 783-790 (1993). (Pubitemid 23164680)
25. Iso H, Folson AR, Koike KA, et al. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: correlates in nonsmoking Japanese and Caucasian men and women. Thromb. Haemost. 70(3), 475-480 (1993). (Pubitemid 23254679)
26. Murata M. Genetic polymorphisms associated with thrombotic disorders in the Japanese population. Fibrinolysis Proteolysis 14, 155-164 (2000). (Pubitemid 30409288)
27. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42(5), 976-982 (1992).
28. Yamaguchi T, Kikuchi H, Hayakawa H, et al. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In: Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ (Eds). Springer-Verlag, Tokyo, Japan, 223-229 (1995).
29. Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37(7), 1810-1815 (2006). (Pubitemid 44297734)
30. Toyoda K, Koga M, Naganuma M, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients; general outcomes and prognostic factors from the SAMURAI register. Stroke 40(11), 3591-3595 (2009).
31. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke 41(3), 461-465 (2010).
32. Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 41(9), 1984-1989 (2010).
33. The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke study. Stroke 35(4), 904-912 (2004).
34. Alexandrov AV. Ultrasound identification and lysis of clots. Stroke 35(Suppl. 1), 2722-2725 (2004). (Pubitemid 39458379)
35. Huang P, Chen CH, Yang YH, Lin RT, Lin FC, Liu CK. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. Cerebrovasc. Dis. 22(5-6), 423-428 (2006). (Pubitemid 44681119)
36. Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: the first prospective evaluation. Clin. Neurol. Neurosurg. 108(6), 549-552 (2006). (Pubitemid 44189093)
37. Padma MV, Singh MB, Bhatia R, et al. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol. India 55(1), 46-49 (2007).
38. Pandian JD, Sethi V, Dhillon R, et al. Is intravenous thrombolysis feasible in a developing country? Cerebrovasc. Dis. 20(2), 134-136 (2005). (Pubitemid 41160214)
39. Sharma VK, Tsivgoulis G, Tan JH, Ong BKC, Chan BPL, Teoh HL. Feasibility and safety of intravenous thrombolysis in multiethnic asian stroke patients in Singapore. J. Stroke Cerebrovasc. Dis. 19(6), 424-430 (2010).
40. Poungvarin N. Stroke in the developing world. Lancet 352(Suppl. 3), 19-22 (1998). (Pubitemid 128643741)
41. Wang Y, Wu D, Zhao X, et al. Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing. Surg. Neurol. 72(Suppl. 1), S2-S7 (2009).
42. Pandian JD, Srikanth V, Read SJ, Thrift AG. Poverty and stroke in India: a time to act. Stroke 38(11), 3063-3069 (2007). (Pubitemid 350035705)
43. Heeley E, Anderson CS, Huang Y, et al. Role of health insurance in averting economic hardship in families following acute stroke in China. Stroke 40(6), 2149-2156 (2009).
44. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1), 35-41 (1993). (Pubitemid 23014379)
45. Yoneda Y, Yamamoto S, Hara Y, et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin. Neurol. Neurosurg. 109(7), 567-570 (2007). (Pubitemid 47023024)
46. Minematsu K, Yamaguchi T, Omae T. Spectacular shrinking deficit: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology 42(1), 157-162 (1992).
47. Sharma SR, Sharma N. Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective. Ann. Indian Acad. Neurol. 11(4), 221-224 (2008).
48. Nguyen TH, Truong ATL, Ngo MB, et al. Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam thrombolysis registry. Eur. J. Neurol. 17(9), 1188-1192 (2010).
49. Wasay M, Barohi H, Malik A, Yousuf A, Awan S, Kamal AK. Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan. Neurol. Sci. 31(2), 223-225 (2010).
50. Hsu YC, Sung SF, Ong CT, Wu CS, Su YH. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. Acta Neurol. Taiwan 18(1), 14-20 (2009).
51. Chao AC, Hsu HY, Chung CP, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in chinese patients. The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study. Stroke 41(5), 885-890 (2010).
52. Lau AY, Soo YO, Graham CA, et al. An expedited stroke triage pathway is the key to shortening the door-to-needle time in delivery of thrombolysis treatment. Hong Kong Med. J. 16(6), 455-462 (2010).
53. Boddu DB, Prasad RG, Bandaru VCSS, et al. Predictors of major neurologic improvement after intravenous thrombolysis in acute ischemic stroke: a hospital based study from Hyderabad, India. Ann. Indian Acad. Neurol. 58(3), 403-406 (2010).
54. Zhou XY, Wanga SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J. Clin. Neurosci. 17(8), 988-992 (2010).
55. Muengtaweepongsa S, Dharmasaroja P, Kummark U. Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country. J. Stroke Cerebrovasc. Dis. doi:10.1016/j. jstrokecerebrovasdis .2010.03.017 (2011) (Epub ahead of print).
56. Salam KA, Ummer K, Pradeep Kumar VG, Noone ML, Laila A, Ragini J. Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008. J. Clin. Neurosci. 16(10), 1276-1278 (2009).
57. OpenEpi: Open Source Epidemiologic Statistics for Public Health. www.OpenEpi.com